semaglutide 1.75 mg Glucagon-like peptide 1 (GLP-1) medications have emerged as a potent tool for weight loss in a country where 40% of the population battles obesity. For individuals long plagued by weight issues and Wegovy (semaglutide) Injector 1.7 mg/0.75 mL FDA approves obesity drug that

Maintain the largest PE registry for research and outcomes improvement

antiemetics, antibiotics, etc) which can prolong the QTc or lower the threshold for arrhythmogenesis

However, the costly prescriptions, weekend injections, and routine doctor visits can become too overwhelming

For people taking between 0.5 mg and 2.4 mg of subcutaneous semaglutide, nausea increased from 23% of those taking 0.5 mg to 68% of those taking 2.4 mg, and vomiting increased from 9% to 45%

On the other hand, factors such as direct drug toxicity, abnormal vascular regulation, or blood glucose fluctuations may induce acute optic nerve injury such as NAION [4]